Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial by Eggermont, Alexander M M, Prof, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Céleste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Konto, Cyril, MD, Hoos, Axel, MD, de Pril, Veerle, MSc, Gurunath, Ravichandra Karra, MD, de Schaetzen, Gaetan, PhD, Suciu, Stefan, PhD, Testori, Alessandro, MD

Get full text

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study by Yokota, Kenji, Uchi, Hiroshi, Uhara, Hisashi, Yoshikawa, Shusuke, Takenouchi, Tatsuya, Inozume, Takashi, Ozawa, Kentaro, Ihn, Hironobu, Fujisawa, Yasuhiro, Qureshi, Anila, Pril, Veerle, Otsuka, Yasushi, Weber, Jeffrey, Yamazaki, Naoya

Get full text

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival by Mandalá, Mario, Larkin, James, Ascierto, Paolo A, Del Vecchio, Michele, Gogas, Helen, Cowey, C Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey

Get full text

Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab: Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melan... by WEBER, Jeffrey S, DUMMER, Reinhard, DE PRIL, Veerle, LEBBE, Celeste, HODI, F. Stephen

Get full text

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase... by Ascierto, Paolo A, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M, Dalle, Stephane, Cowey, C Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O, Maio, Michele, Middleton, Mark R, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A, Millward, Michael, Khushalani, Nikhil I, Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James, Weber, Jeffrey

Get full text

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 180... by Eggermont, Alexander M.M., Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo Antonio, Richards, Jon M., Lebbe, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Hosein, Fareeda, de Pril, Veerle, Kicinski, Michal, Suciu, Stefan, Testori, Alessandro

Get full text

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational... by Coens, Corneel, MSc, Suciu, Stefan, PhD, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Celeste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Bottomley, Andrew, PhD, Kotapati, Srividya, PharmD, de Pril, Veerle, Testori, Alessandro, MD, Eggermont, Alexander M M, Prof

Get full text

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) by Long, Georgina V., Schadendorf, Dirk, Vecchio, Michele Del, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen J., Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo, Giacomo, Anna Maria Di, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, Menzies, Alexander, Re, Sandra, Bas, Tuba O., de Pril, Veerle, Tenney, Daniel, Tang, Hao, Weber, Jeffrey S.

Get full text

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials by Wolchok, Jedd D, Weber, Jeffrey S, Hamid, Omid, Lebbé, Celeste, Maio, Michele, Schadendorf, Dirk, de Pril, Veerle, Heller, Kevin, Chen, Tai-Tsang, Ibrahim, Ramy, Hoos, Axel, O'Day, Steven J

Get full text

Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality o... by Coens, Corneel, Suciu, Stefan, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A., Richards, Jon M., Lebbe, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Kotapati, Srividya, de Pril, Veerle, Testori, Alessandro, Eggermont, Alexander

Get full text

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab by Weber, Jeffrey S., Dummer, Reinhard, de Pril, Veerle, Lebbé, Celeste, Hodi, F. Stephen

Get full text

A Phase III study at high risk for recurrence by Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen

Get full text

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in pat... by Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen

Get full text

Coadministration of muraglitazar plus glyburide: Improvement of glycaemic and lipid profiles in patients with type 2 diabetes by Rubin, Cindy J., De Pril, Veerle, Fiedorek, Fred T.

Request full text